Biohaven Ltd.
BHVNNYSEHealthcare · Pharmaceutical Preparations · D8 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$745.4M | −$885.1M | −$436.1M | −$567.9M | −$218.9M |
| Net income | −$738.8M | −$846.4M | −$408.2M | −$570.3M | −$213.8M |
| Total assets | $451.4M | $615.1M | $513.2M | $661.8M | $142.1M |
| Total liabilities | $399.4M | $191.7M | $85.2M | $123.0M | $47.4M |
| Equity | $52.1M | $423.4M | $428.0M | $538.8M | $34.7M |
| EPS (diluted) | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 |
| Shares out. | 102.1M | 81.6M | 68.2M | 68.2M | 0 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −1418.8%
- Return on assets
- −163.7%
- Return on capital (ROCE)
- −222.2%
- Liabilities / assets
- 88.5%
- Debt / equity
- 7.67×
- Book value / share
- $0.51
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -22.34distress
- Accruals / assets
- −28.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2022-02-18Troriluzole in Adult Participants With Spinocerebellar Ataxia
- Phase 3Active Not Recruitingreadout ~2024-09-25A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
- Phase 2/3Recruitingreadout ~2026-05Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
- Phase 2Active Not Recruitingreadout ~2026-09Taldefgrobep Alfa in Adults With Overweight and Obesity
- Phase 1Enrolling By Invitationreadout ~2026-11A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
- Phase 2/3Recruitingreadout ~2026-12A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
- Phase 2Enrolling By Invitationreadout ~2026-12Long-term Safety and Tolerability of BHV-7000
- Phase 1Recruitingreadout ~2027-07Study of BHV-1400 in IgA Nephropathy
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Suvretta Capital Management, LlcPassive (13G)Feb 13, 2026
- Vanguard Group IncPassive (13G)Oct 30, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 24.1M | 11.9 | -3.1% |
| Apr 30, 2026 | 24.9M | 14.4 | +4.6% |
| Apr 15, 2026 | 23.8M | 12.4 | +0.0% |
| Mar 31, 2026 | 23.8M | 9.4 | +8.6% |
| Mar 13, 2026 | 21.9M | 8.2 | +4.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 27, 2026
- Other material eventMay 5, 2026
- Results of operationsMay 4, 2026
- Shareholder voteMay 4, 2026
- Results of operationsMar 2, 2026
- Regulation FD disclosureJan 12, 2026
- Other material eventJan 7, 2026
- Other material eventNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.